Total Revenue
Breakdown
| Segment | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| TYSABRI | $462.20M | $406.10M | $415.40M | $381.50M | $454.60M | $431.80M | $397.50M | $441.50M |
| SPINRAZA | $429.10M | $381.40M | $421.40M | $423.90M | $392.70M | $374.00M | $356.20M | $374.00M |
| VUMERITY | $165.80M | $158.10M | $176.60M | $138.80M | $212.30M | $214.60M | $181.10M | $179.00M |
| AVONEX | $182.80M | $176.20M | $170.00M | $166.80M | $177.70M | $188.50M | $162.50M | $163.20M |
| SKYCLARYS | $100.00M | $102.30M | $102.20M | $123.90M | $130.30M | $132.90M | $133.40M | $150.70M |
| BENEPALI | $117.30M | $118.10M | $125.00M | $111.30M | $112.10M | $121.90M | $107.90M | $122.10M |
| TECFIDERA | $252.20M | $232.80M | $227.80M | $206.10M | $193.60M | $168.20M | $111.80M | $109.50M |
| PLEGRIDY | $68.10M | $61.30M | $66.00M | $59.50M | $69.00M | $58.40M | $63.20M | $64.30M |
| ZURZUVAE | $14.90M | $22.00M | $22.90M | $27.70M | $46.40M | $55.30M | $65.70M | $55.40M |
| IMRALDI | $53.20M | $54.10M | $51.00M | $47.40M | $46.70M | $52.60M | $43.50M | $49.60M |
| QALSODY | $5.00M | $11.10M | $11.70M | $15.50M | $20.00M | $26.40M | $25.00M | $32.50M |
| FLIXABI | $13.10M | $16.20M | $16.10M | $13.10M | $14.30M | $15.30M | $9.90M | $10.50M |
| FAMPYRA | $18.70M | $19.40M | $14.40M | $300.00K | $0.00 | $0.00 | $1.10M | $0.00 |
| BYOOVIZ | $13.70M | $8.00M | $9.30M | $8.90M | $8.60M | $7.00M | $7.90M | $0.00 |
| TOFIDENCE | $800.00K | $200.00K | $100.00K | $100.00K | $0.00 | $0.00 | $600.00K | $0.00 |
| FUMADERM And ADUHELM | $2.70M | $2.10M | $2.70M | $1.70M | $400.00K | $0.00 | $0.00 | $0.00 |
| Total | $2.46B | $2.47B | $2.45B | $2.43B | $2.65B | $2.53B | $2.28B | $2.48B |
Segments
Product revenue, netView metric
Revenue from anti-CD20 therapeutic programsView metric
Alzheimer's collaboration revenueView metric
Contract manufacturing, royalty and other revenueView metric
TECFIDERAView metric
VUMERITYView metric
FumarateView metric
AVONEXView metric
PLEGRIDYView metric
InterferonView metric
TYSABRIView metric
FAMPYRAView metric
MS Product RevenuesView metric
SPINRAZAView metric
SKYCLARYSView metric
QALSODYView metric
Rare Disease Product RevenueView metric
BENEPALIView metric
IMRALDIView metric
FLIXABIView metric
BYOOVIZView metric
TOFIDENCEView metric
BiosimilarsView metric
ZURZUVAEView metric
FUMADERM And ADUHELMView metric
OtherView metric
Royalty Attributed To OCREVUSView metric
Alzheimer's CollaborationView metric
Contract manufacturing revenueView metric
Royalty and other revenueView metric